Advancing Therapeutic Options Around the World
Astellas Anemia Partnership
FibroGen and Astellas have been collaborating on hypoxia-inducible factor (HIF) anemia programs since 2004, first for Japan, and then for a broader territory covering Europe, the Middle East, the Commonwealth of Independent States, and South Africa. The strategic collaboration between the two companies delivered roxadustat as the first among all hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors to be approved in Japan, Europe, and numerous countries.
AstraZeneca Anemia Partnership
In 2013, FibroGen and AstraZeneca entered into an anemia partnership for roxadustat in the U.S., China, and all other markets not licensed to Astellas. Our collaboration with AstraZeneca leveraged FibroGen China’s strategy to bring this world-class innovation to China as the first country for any hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor to be approved in the world.
Eluminex Biosynthetic Cornea Partnership
In July 2021, Eluminex exclusively licensed global rights from FibroGen to develop and commercialize an investigational biosynthetic cornea derived from recombinant human collagen Type III for patients with corneal blindness. The Eluminex biosynthetic cornea (EB-301) is a clinical stage corneal stromal substitute that will be developed for the China market initially. Additionally, Eluminex licensed all rights globally to develop other products based on the underlying recombinant human collagen Type III.
In May 2023, FibroGen entered into an exclusive license with Fortis Therapeutics for FOR46 (FG-3246), a potential first-in-class Phase I antibody-drug conjugate (ADC) targeting a novel epitope on CD46. FG-3246 is being developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). FibroGen anticipates the initiation of a Phase II trial in metastatic castration-resistant prostate cancer, or mCRPC, in the second half of 2024 with the potential for additional trials targeting other CD46 expressing cancers. As part of the clinical development strategy, FibroGen will also continue to work with UCSF to develop a PET-based biomarker utilizing a radiolabeled version of the targeting antibody (PET46) for patient selection.
In June 2021, FibroGen exclusively licensed all product candidates in HiFiBiO Therapeutics’ Galectin-9 program, obtaining sole rights to develop and commercialize products worldwide. FibroGen also obtained an exclusive option to two other HiFiBiO programs, and subsequently exercised one of its exclusive options licensing all product candidates in HiFiBiO’s CCR8 program. This transformative partnership enables up to two INDs, expanding our oncology development pipeline in FibroGen’s core research areas.